Northland Capital Partners View on the City - Arian Silver Corp, Keras Resources


Keras Resources (LON:KRS) – CORP: Klondyke update

Market Cap: £7.2m; Current Price: 0.5p

High-grade gold results from RC drill programme

Keras Resources has received the assay results from the outstanding six RC holes from the drill programme completed in November at the Klondyke Gold Project, located in Australia.

Results include; 6m at 4.45g/t Au from 24m and 4m at 5.5g/t Au from 86m (KKC008), 2m at 5.77g/t Au from 6m (KKC003) and 23m at 2.68g/t Au from 2m (KK007).

Samples from significant intercepts are currently being analysed by screen fire assay to provide more accurate grades.

The 2017 drill programme designed to target expansion of the current JORC compliant mineral resource estimate of 374,000oz at a grade of 2.08g/t Au, will be finalised following the fire assay results.

NORTHLAND CAPITAL PARTNERS VIEW: Another positive set of drill results from Keras Resources at the Klondyke Gold Project. The Company believes that the high-grade gold intervals encountered at depth suggest that the project may have the potential for underground operations, as well as, an initial open pit operation. To date the Company has only tested 1.4km of the 7.5km strike of the Klondyke trend, highlighting significant upside potential.


Arian Silver Corporation (LON:AGQ) – CORP: San Celso update

Market Cap: £1.1m; Current Price: 0.625p

High-grade silver results at surface

Arian Silver has defined several largely unexploited high-grade silver veins at the San Celso Project, located in Mexico.

Surface sample results include; 1.05m at 395.9g/t Ag (37554), 350.5g/t Ag (SCD009) and 346.9g/t Ag SCD010.

NORTHLAND CAPITAL PARTNERS VIEW: Arian Silver believes that the silver-lead-zinc mineralisation at the San Celso Project is indicative of a low sulphidation epithermal system. Historic mining terminated at the water table (c. 90m) and the Company believes there is considerable potential to define additional mineralisation at depth on both the San Celso and Las Cristinitas veins.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Amryt Pharma releases Q-2 financials that show strong revenue growth as...

Amryt Pharma (Nasdaq: AMYT) CEO Dr Joe Wiley joined Steve Darling from Proactive with news the company saw a nice increase in revenue as they released their Q-2 numbers. Dr Wiley talked about some of the numbers and what was driving that revenue. Wiley also told Proactive the company has, for...

2 hours, 56 minutes ago

2 min read